Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T17:34:00.914Z.
Calculation as of: 2026-10-06T17:34:00.914Z.
Quote observation: 2026-10-06T17:29:27.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 960fabb584be58b0360682ce889880f50a04fda9407a8e289859ad1a2016d30f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$188.55M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$183.94M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$181.71M
Price/FCF Ratio
N/A
TTM Avg
28.71
3Y Avg
28.66
5Y Avg
28.66
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| RxSight, Inc. (RXST) | $191.67M | N/A | N/A | N/A | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $188.55M | N/A | N/A | N/A | N/A |
| Surrozen, Inc. (SRZN)vs › | $197.18M | N/A | N/A | N/A | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $183.94M | N/A | N/A | N/A | N/A |
| Exagen Inc. (XGN)vs › | $200.35M | N/A | N/A | N/A | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $183.32M | N/A | N/A | N/A | N/A |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $181.71M | N/A | 28.71 | 28.66 | 28.66 |
| Alector, Inc. (ALEC)vs › | $203.98M | N/A | 3.22 | 3.23 | 4.48 |
| Yarrow Bioscience Inc (YARW)vs › | $178.50M | N/A | N/A | N/A | N/A |
| Sionna Therapeutics, Inc. (SION)vs › | $205.31M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
